Mitsuya Ito
YOU?
Author Swipe
View article: Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis
Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis Open
View article: 221P Long-term outcomes of eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer: Results of the randomized JBCRG-22 study
221P Long-term outcomes of eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer: Results of the randomized JBCRG-22 study Open
View article: Accumulation of CD56<sup>+</sup> CD16<sup>-</sup> Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer
Accumulation of CD56<sup>+</sup> CD16<sup>-</sup> Natural Killer Cells in Response to Preoperative Chemotherapy for Breast Cancer Open
The accumulation of the immunoregulatory CD56+ CD16- NK cell subset in the peripheral blood before and after chemotherapy may lead to the production of cytokines that induce an antitumor immune response. Activation of…
View article: Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks) Open
Purpose The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) as compared with the standard TCbHP regim…
View article: Efficacy and safety of pegfilgrastim biosimilar <scp>MD</scp>‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase <scp>III</scp>
Efficacy and safety of pegfilgrastim biosimilar <span>MD</span>‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase <span>III</span> Open
Introduction Pegfilgrastim is indicated to decrease the incidence of chemotherapy‐induced febrile neutropenia. It is the first granulocyte‐colony stimulating factor approved for prophylactic use regardless of carcinoma type and is marketed…
View article: Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services Open
A certain number of patients with early-stage breast cancer prefer nonsurgical treatment, and it is important to provide information regarding the availability of RFA for early-stage breast cancer under the PPHS.Trial registration: registe…
View article: Outcomes in patients with non‐invasive breast carcinoma
Outcomes in patients with non‐invasive breast carcinoma Open
Background and Aim Non‐invasive breast carcinoma is considered to be localized disease and is distinguished from invasive ductal and lobular carcinomas. The local recurrence of non‐invasive carcinoma after surgery may lead to development o…
View article: Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with <i>nab</i>-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)
Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with <i>nab</i>-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031) Open
Background In the global phase III IMpassion031 study, neoadjuvant atezolizumab plus nab-paclitaxel/anthracycline-based chemotherapy improved pathological complete response in patients with early stage triple-negative breast cancer. Here, …
View article: Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients
Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients Open
View article: Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer
Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer Open
View article: Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial Open
Neoadjuvant chemotherapy using nab-PTX with trastuzumab every 3 weeks followed by FEC was suitably tolerated and associated with a high pCR rate of 55% for patients with HER2-positive breast cancer.
View article: Supplementary Material for: Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study
Supplementary Material for: Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study Open
Introduction: Previous studies have suggested that the efficacy of eribulin is influenced by the activity of antitumor immunity of patients. Absolute lymphocyte count (ALC) and the neutrophil/lymphocyte ratio (NLR) are easily…
View article: Safety and Efficacy Evaluation of Pertuzumab for the Neoadjuvant Treatment with HER2-positive Breast Cancer
Safety and Efficacy Evaluation of Pertuzumab for the Neoadjuvant Treatment with HER2-positive Breast Cancer Open
HER2陽性原発乳癌に対するpertuzumabの術前化学療法としての使用は，NeoSphere試験でdocetaxel+trastuzumabに上乗せされることで有意にpCR率を改善することが示された（docetaxel+trastuzumab:29.0％，docetaxel+trastuzumab+pertuzumab:45.8％）．当院でのpertuzumabの術前化学療法としての使用経験を報告する．2015年11月から2019年7月までにHER2陽性原発乳癌の術前化…
View article: The Efficacy and Safety of Lapatinib Plus Capecitabine for HER2-positive Advanced and Recurrent Breast Cancer with Brain Metastases
The Efficacy and Safety of Lapatinib Plus Capecitabine for HER2-positive Advanced and Recurrent Breast Cancer with Brain Metastases Open
今回われわれは，脳転移を伴うHER2陽性転移性乳癌に対してlapatinib+capecitabine（LC）療法を施行し，約9年のlong CRとなった症例を経験した．そこで，2009年7月～2019年4月までに脳転移を伴うHER2陽性転移再発乳癌に対して，当院にてLC療法を施行した16例について，その有効性と安全性について後方視的に検討した．なお，脳転移診断後，全例で局所療法（2例:外科的切除，14例:放射線療法）を施行した後にLC療法を開始した．全体の治療効果はCR:…
View article: Two Cases of HER2-negative Recurrent Breast Cancer Treated with Olaparib as a Second and Third Line of Therapy with Good Responses
Two Cases of HER2-negative Recurrent Breast Cancer Treated with Olaparib as a Second and Third Line of Therapy with Good Responses Open
オラパリブは2018年に本邦で承認されたが，適格症例が多くはないため，その症例報告はいまだ少ない．当院で著効している2例について報告する．症例①:44歳，女性．右乳癌 T2N2aM0 stage IIIA，luminal typeで，術後2年で肺転移にて再発した．ホルモン療法，経口抗癌剤を施行後，BRCA2変異を認め，三次治療としてオラパリブを投与し，8カ月間PRを維持している．症例②:69歳，女性．両側乳癌術後で，左はT2N0M0 stage II A，luminal t…
View article: A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients
A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients Open
View article: Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients
Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients Open
Background Surgery/anesthetic technique‐stimulated immunosuppression may be associated with outcome for cancer patients. Here, the immune responses of patients undergoing day surgery versus hospitalization surgery for breast cancer were co…
View article: Metastatic Cancer of Multiple Organs Diagnosed as Breast Cancer by GCDFP-15—A Case Report—
Metastatic Cancer of Multiple Organs Diagnosed as Breast Cancer by GCDFP-15—A Case Report— Open
症例は53歳，女性．9カ月前から頸部違和感を自覚して近医整形外科を受診．頸椎X線写真撮影にて転移性骨腫瘍を認め，当院紹介となった．造影CT・PET-CTでは多発骨・肝転移を認めたが，原発巣は不明であった．上部消化管内視鏡検査では胃にびらんが多発，十二指腸に発赤・白斑を認め，生検の結果，低分化腺癌を認め，既存の腺管が残存していることから，転移性腫瘍が疑われた．追加の免疫組織化学染色でGCDFP-15が一部陽性であったため，乳癌が疑われ，MRIにて右C・D領域にそれぞれ0.6c…
View article: Clinical Impact of Metronomic Oral Combination Chemotherapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer
Clinical Impact of Metronomic Oral Combination Chemotherapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer Open
目的と方法:HER2陰性転移再発乳癌において，XC （Capecitabine + Cyclophosphamide）療法は経口投与・副作用が軽微な点で患者負担が少ない上，高い奏効を示す魅力的な治療法である．当院でXC療法を施行した67例の治療効果をretrospectiveに検討した．結果:PFS 9.2カ月，OS 31.5カ月，RR 41.8％と良好だった．XC療法は再発後早期投与例で有意にPFSが長かった．有害事象による減量・休薬を行った症例の方が高い治療効果が得られ…
View article: P194 Pathological response to NAC for locally advanced breast cancer using MRI and PET/CT
P194 Pathological response to NAC for locally advanced breast cancer using MRI and PET/CT Open
View article: Efficacy of Dexamethasone for Reducing Rash in Breast Cancer Patients Treated with Docetaxel/Cyclophosphamide Therapy
Efficacy of Dexamethasone for Reducing Rash in Breast Cancer Patients Treated with Docetaxel/Cyclophosphamide Therapy Open
Docetaxel plus cyclophosphamide (TC) therapy is standard adjuvant chemotherapy for breast cancer. In TC therapy, rash frequently occurs and results in decreased quality of life for patients. In this study, we performed a retrospective anal…
View article: A Case of Spindle Cell Carcinoma of The Breast with a Rapid Growth
A Case of Spindle Cell Carcinoma of The Breast with a Rapid Growth Open
症例は41歳，女性．約３年前に左乳房腫瘤を主訴に近医受診．約２cm大の囊胞性腫瘤を認め，細胞診を施行したが，明らかな悪性所見なく経過観察となった．当科受診５カ月前より，腫瘤は急速に増大し，皮膚潰瘍を形成したため，近医再診．再度細胞診を施行し，悪性の診断にて当科紹介となった．初診時，左乳房A領域に潰瘍を伴った手拳大の腫瘤を認め，PET-CTにて左肺S6に径４cm大の空洞形成を伴った肺腫瘤を認めた．確定診断目的に乳房腫瘤に対し針生検を施行し，肺腫瘤に対してはCTガイド下針生検を…